Ocular Therapeutix, Inc OCUL
We take great care to ensure that the data presented and summarized in this overview for OCULAR THERAPEUTIX, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OCUL
View all-
Deep Track Capital, LP Greenwich, CT14.3MShares$165 Million3.66% of portfolio
-
Summer Road LLC West Palm Beach, FL13.9MShares$160 Million98.53% of portfolio
-
Vr Adviser, LLC New York, NY12.8MShares$147 Million22.59% of portfolio
-
Black Rock Inc. New York, NY11.5MShares$133 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.36MShares$96.6 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.06MShares$93.1 Million0.96% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.32MShares$61.4 Million9.39% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.2MShares$60.1 Million0.07% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.81MShares$55.6 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.42MShares$39.5 Million0.0% of portfolio
Latest Institutional Activity in OCUL
Top Purchases
Top Sells
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Insider Transactions at OCUL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 11
2025
|
Merilee Raines Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+22.98%
|
-
|
Jun 11
2025
|
Seung Suh Hong Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+22.98%
|
-
|
Jun 11
2025
|
Adrienne L Graves Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+21.88%
|
-
|
Jun 11
2025
|
Charles M Warden Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+13.94%
|
-
|
Jun 11
2025
|
Leslie J. Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+21.4%
|
-
|
Jun 11
2025
|
Richard L Md Lindstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+8.91%
|
-
|
Jun 02
2025
|
Nadia Waheed Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,861
-6.28%
|
$110,888
$8.05 P/Share
|
May 23
2025
|
Peter Kaiser Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,974
-1.42%
|
$20,818
$7.17 P/Share
|
May 23
2025
|
Sanjay Nayak Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,862
-0.66%
|
$13,034
$7.17 P/Share
|
May 23
2025
|
Pravin Dugel Director |
SELL
Open market or private sale
|
Direct |
21,219
-0.6%
|
$148,533
$7.18 P/Share
|
May 23
2025
|
Jeffrey S. Heier Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,024
-1.14%
|
$21,168
$7.18 P/Share
|
May 08
2025
|
Richard L Md Lindstrom Director |
BUY
Open market or private purchase
|
Direct |
10,000
+5.47%
|
$60,000
$6.96 P/Share
|
Feb 24
2025
|
Jeffrey S. Heier Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,061
-1.14%
|
$18,366
$6.87 P/Share
|
Feb 24
2025
|
Pravin Dugel Director |
SELL
Open market or private sale
|
Direct |
21,475
-0.61%
|
$128,850
$6.87 P/Share
|
Feb 24
2025
|
Sanjay Nayak Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,895
-0.66%
|
$11,370
$6.84 P/Share
|
Feb 24
2025
|
Peter Kaiser Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,009
-1.41%
|
$18,054
$6.87 P/Share
|
Feb 11
2025
|
Sanjay Nayak Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
111,000
+28.0%
|
-
|
Feb 11
2025
|
Donald Notman Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+27.16%
|
-
|
Feb 11
2025
|
Nadia Waheed Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
79,000
+26.36%
|
-
|
Feb 11
2025
|
Pravin Dugel Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750,000
+33.86%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 3.52M shares |
---|---|
Open market or private purchase | 10K shares |
Open market or private sale | 141K shares |
---|